NeuroDerm (NDRM): Hiking PT 43% After Management Meeting - Jefferies

September 6, 2016 8:57 AM EDT
Get Alerts NDRM Hot Sheet
Price: $18.85 +1.62%

Rating Summary:
    5 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 26 | Down: 29 | New: 38
Trade NDRM Now!
Join SI Premium – FREE

Get the Pulse of the Market with's Pulse Picks. Get your Free Trial here.

Jefferies analyst, Peter Welford, reiterated his Buy rating on shares of Neuroderm Ltd (NASDAQ: NDRM) and raised his price target to $40 from $28. The analyst met management in Israel and gained confidence in the commercial potential of ND0612L/H, raising his WW peak sales to $1.75bn from $1.3bn. He is keeping a conservative 40% probability of a 2019E launch however.

On a side note, the analyst believes Sunovion's recent acquisition of peer Cynapsus illustrates the appetite for assets in Parkinson's.

For an analyst ratings summary and ratings history on Neuroderm Ltd click here. For more ratings news on Neuroderm Ltd click here.

Shares of Neuroderm Ltd closed at $16.08 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst EPS View, Analyst PT Change, Management Comments

Related Entities

Jefferies & Co, Definitive Agreement

Add Your Comment